Literature DB >> 9632756

Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain.

M W Frazier1, X He, J Wang, Z Gu, J L Cleveland, G P Zambetti.   

Abstract

Mutation of the p53 tumor suppressor gene is the most common genetic alteration in human cancer, and tumors that express mutant p53 may be more aggressive and have a worse prognosis than p53-null cancers. Mutant p53 enhances tumorigenicity in the absence of a transdominant negative mechanism, and this tumor-promoting activity correlates with its ability to transactivate reporter genes in transient transfection assays. However, the mechanism by which mutant p53 functions in transactivation and its endogenous cellular targets that promote tumorigenicity are unknown. Here we report that (i) mutant p53 can regulate the expression of the endogenous c-myc gene and is a potent activator of the c-myc promoter; (ii) the region of mutant p53 responsiveness in the c-myc gene has been mapped to the 3' end of exon 1; (iii) the mutant p53 response region is position and orientation dependent and therefore does not function as an enhancer; and (iv) transactivation by mutant p53 requires the C terminus, which is not essential for wild-type p53 transactivation. These data suggest that it may be possible to selectively inhibit mutant p53 gain of function and consequently reduce the tumorigenic potential of cancer cells. A possible mechanism for transactivation of the c-myc gene by mutant p53 is proposed.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9632756      PMCID: PMC108956          DOI: 10.1128/MCB.18.7.3735

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  51 in total

1.  Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis.

Authors:  G Shaulsky; N Goldfinger; A Ben-Ze'ev; V Rotter
Journal:  Mol Cell Biol       Date:  1990-12       Impact factor: 4.272

2.  Rearrangement of the p53 gene in human osteogenic sarcomas.

Authors:  H Masuda; C Miller; H P Koeffler; H Battifora; M J Cline
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

3.  Synergistic activation of transcription by CBP and p53.

Authors:  W Gu; X L Shi; R G Roeder
Journal:  Nature       Date:  1997-06-19       Impact factor: 49.962

4.  Binding and modulation of p53 by p300/CBP coactivators.

Authors:  N L Lill; S R Grossman; D Ginsberg; J DeCaprio; D M Livingston
Journal:  Nature       Date:  1997-06-19       Impact factor: 49.962

5.  DNA sequences that mediate attenuation of transcription from the mouse protooncogene myc.

Authors:  S Wright; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1989-01       Impact factor: 11.205

6.  A block to elongation is largely responsible for decreased transcription of c-myc in differentiated HL60 cells.

Authors:  D L Bentley; M Groudine
Journal:  Nature       Date:  1986 Jun 12-18       Impact factor: 49.962

7.  The p53 tumour suppressor protein is phosphorylated at serine 389 by casein kinase II.

Authors:  D W Meek; S Simon; U Kikkawa; W Eckhart
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

8.  Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl.

Authors:  J L Cleveland; M Dean; N Rosenberg; J Y Wang; U R Rapp
Journal:  Mol Cell Biol       Date:  1989-12       Impact factor: 4.272

9.  Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes.

Authors:  P W Hinds; C A Finlay; R S Quartin; S J Baker; E R Fearon; B Vogelstein; A J Levine
Journal:  Cell Growth Differ       Date:  1990-12

10.  Intragenic pausing and anti-sense transcription within the murine c-myc locus.

Authors:  A Nepveu; K B Marcu
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  69 in total

1.  PTGF-beta, a type beta transforming growth factor (TGF-beta) superfamily member, is a p53 target gene that inhibits tumor cell growth via TGF-beta signaling pathway.

Authors:  M Tan; Y Wang; K Guan; Y Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

2.  Integrity of the N-terminal transcription domain of p53 is required for mutant p53 interference with drug-induced apoptosis.

Authors:  D Matas; A Sigal; P Stambolsky; M Milyavsky; L Weisz; D Schwartz; N Goldfinger; V Rotter
Journal:  EMBO J       Date:  2001-08-01       Impact factor: 11.598

3.  Modification of the erythroid transcription factor GATA-1 by SUMO-1.

Authors:  Licio Collavin; Monica Gostissa; Fabio Avolio; Paola Secco; Antonella Ronchi; Claudio Santoro; Giannino Del Sal
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-01       Impact factor: 11.205

Review 4.  Expression of CDK8 and CDK8-interacting Genes as Potential Biomarkers in Breast Cancer.

Authors:  Eugenia V Broude; Balázs Győrffy; Alexander A Chumanevich; Mengqian Chen; Martina S J McDermott; Michael Shtutman; James F Catroppo; Igor B Roninson
Journal:  Curr Cancer Drug Targets       Date:  2015       Impact factor: 3.428

Review 5.  Synthetic lethal interactions for the development of cancer therapeutics: biological and methodological advancements.

Authors:  Shinji Mizuarai; Hidehito Kotani
Journal:  Hum Genet       Date:  2010-10-26       Impact factor: 4.132

6.  Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis.

Authors:  Anjana K Negi; Shevali Kansal; Archana Bhatnagar; Navneet Agnihotri
Journal:  Tumour Biol       Date:  2013-09-21

7.  Mutant p53 is a transcriptional co-factor that binds to G-rich regulatory regions of active genes and generates transcriptional plasticity.

Authors:  Timo Quante; Benjamin Otto; Marie Brázdová; Iva Kejnovská; Wolfgang Deppert; Genrich V Tolstonog
Journal:  Cell Cycle       Date:  2012-08-21       Impact factor: 4.534

8.  Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Authors:  Sue Haupt; Catherine Mitchell; Vincent Corneille; Jake Shortt; Stephen Fox; Pier Paolo Pandolfi; Mireia Castillo-Martin; Dennis M Bonal; Carlos Cordon-Cardo; Guillermina Lozano; Ygal Haupt
Journal:  Cell Cycle       Date:  2013-05-08       Impact factor: 4.534

9.  TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype.

Authors:  David A Sallman; Amy F McLemore; Amy L Aldrich; Rami S Komrokji; Kathy L McGraw; Abhishek Dhawan; Susan Geyer; Hsin-An Hou; Erika A Eksioglu; Amy Sullivan; Sarah Warren; Kyle J MacBeth; Manja Meggendorfer; Torsten Haferlach; Steffen Boettcher; Benjamin L Ebert; Najla H Al Ali; Jeffrey E Lancet; John L Cleveland; Eric Padron; Alan F List
Journal:  Blood       Date:  2020-12-10       Impact factor: 22.113

10.  Mutant p53 attenuates the SMAD-dependent transforming growth factor beta1 (TGF-beta1) signaling pathway by repressing the expression of TGF-beta receptor type II.

Authors:  Eyal Kalo; Yosef Buganim; Keren E Shapira; Hilla Besserglick; Naomi Goldfinger; Lilach Weisz; Perry Stambolsky; Yoav I Henis; Varda Rotter
Journal:  Mol Cell Biol       Date:  2007-09-17       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.